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IntroductIon
The genera Marburgvirus and Ebolavirus comprise the family 
Filoviridae, which contains the etiological agents that cause 
Marburg virus (MARV) disease and Ebola virus (EBOV) 
disease, respectively. EBOV recently caused an outbreak of 
unprecedented scale, spanning 2 yr and infecting >28,000 in-
dividuals. Previously, the largest filovirus outbreaks had num-
bered in the tens to hundreds. Whereas EBOV is responsible 
for the greatest number of human filovirus infections, MARV, 
Sudan virus (SUDV), and Bundibugyo virus (BDBV) have 
all caused outbreaks in humans that numbered >100 cases, 
twice in the cases of MARV and SUDV. EBOV may garner 
much of the attention, but it is only one of several filoviruses 
that could potentially kindle outbreaks of massive scale. To 
date, there have been 11 incidences of MARV transmission 
to the human population that spawned outbreaks of vary-
ing size. Whereas many outbreaks have been of limited scale, 
afflicting fewer than five individuals per instance, two out-
breaks alone account for 406 cases of MARV infections that 
had fatality rates of 83 and 90% (Bausch et al., 2006; Towner 
et al., 2006). Furthermore, a precedent already exists for the 
importation of MARV to other countries from travelers that 
visited MARV hot spots (Centers for Disease Control and 
Prevention (CDC), 2009; van Paassen et al., 2012), which was 
a concern during the 2013–2015 EBOV outbreak in west-
ern Africa. Simple luck or coincidence has thus far prevented 
these MARV outbreaks from growing into larger problems.
In 2012 alone, four distinct filovirus outbreaks oc-
curred in Africa. Three outbreaks occurred in Uganda (two 
of SUDV and one of MARV), with the fourth occurring in 
the Democratic Republic of Congo (BDBV; Albariño et al., 
2013). Sequencing of viral genomes isolated from two fatal 
cases of MARV in 2012 indicated a high similarity with the 
original MARV isolate (Amman et al., 2012; Albariño et 
al., 2013). MARV case fatality rates (CFRs) vary from 23 to 
90% in cases where more than one individual was infected. 
The CFR for the MARV outbreak in 2012 was 27% (n = 
15 confirmed cases), in keeping with the outbreak that was 
caused by the MARV isolate bearing the greatest similarity 
to the 2012 isolates (original MARV isolate in 1967; CFR 
of 23%; Bukreyev et al., 1995; Slenczka and Klenk, 2007; 
Amman et al., 2012; Albariño et al., 2013).
until recently, immune responses in filovirus survivors remained poorly understood. Early studies revealed IgM and IgG re-
sponses to infection with various filoviruses, but recent outbreaks have greatly expanded our understanding of filovirus im-
mune responses. Immune responses in survivors of Ebola virus (EBoV) and Sudan virus (SudV) infections have provided the 
most insight, with t cell responses as well as detailed antibody responses having been characterized. Immune responses to 
Marburg virus (MArV), however, remain almost entirely uncharacterized. We report that immune responses in MArV survivors 
share characteristics with EBoV and SudV infections but have some distinct differences. MArV survivors developed multivar-
iate cd4+ t cell responses but limited cd8+ t cell responses, more in keeping with SudV survivors than EBoV survivors. In stark 
contrast to SudV survivors, rare neutralizing antibody responses in MArV survivors diminished rapidly after the outbreak. 
these results warrant serious consideration for any vaccine or therapeutic that seeks to be broadly protective, as different 
filoviruses may require different immune responses to achieve immunity.
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Profiles of immunity developed in filovirus survivors 
have begun to shed light on immune responses that had been 
understudied. Antibody responses to EBOV had previously 
been relatively well characterized, with IgM responses being 
succeeded by IgG in survivors, whereas nonsurvivors fail to 
develop IgG responses (Baize et al., 1999; Ksiazek et al., 1999) 
Additionally, neutralizing antibody responses have been de-
scribed in cases of EBOV, SUDV, BDBV, and a single case 
of MARV infection (Maruyama et al., 1999; Sobarzo et al., 
2012; Flyak et al., 2015, 2016; Bornholdt et al., 2016). A re-
cent study has directly shown that EBOV survivors treated 
in the U.S., either after exposure in western Africa or after 
nosocomial infection in the U.S., developed IFN-γ– and 
TNF-positive CD4+ and CD8+ T cell responses to various 
EBOV proteins (McElroy et al., 2015). This was the first 
time antigen-specific responses in T cells had been directly 
demonstrated in human survivors of filovirus infection. A 
subset of EBOV-infected individuals also had elevated levels 
of serum IL-2, IFN-γ, and IL-4 that were measured longi-
tudinally during their treatment in the U.S. (McElroy et al., 
2016). IL-2, IFN-γ, and TNF were also found to be present in 
serum samples from survivors and nonsurvivors of an EBOV 
outbreak in the Democratic Republic of Congo (Villinger et 
al., 1999), whereas TNF was found to be decreased and IFN-γ 
showed no statistical change in serum from BDBV-infected 
individuals (Gupta et al., 2012). Levels of these cytokines were 
not reported in a broad cytokine analysis of serum from the 
2000–2001 SUDV outbreak (McElroy et al., 2014), but previ-
ous studies of serum from that outbreak showed mixed results 
for TNF and IFN-γ by ELI SA and quantitative PCR analyses 
(Sanchez et al., 2004; Hutchinson and Rollin, 2007). A later 
study revealed the presence of CD4+ T cell responses in the 
same SUDV survivor pool, measured >10 yr after the out-
break (Sobarzo et al., 2016). Collectively, these studies have 
provided a detailed description of adaptive immune responses 
in survivors of EBOV, SUDV, and BDBV infection.
It is unknown whether immune responses from MARV 
survivors will present similar profiles to those described for 
other filoviruses, or if there will be critical differences. Be-
yond IgG or IgM ELI SAs performed for diagnostic purposes, 
virtually the entirety of the literature available regarding fi-
lovirus immune responses in humans comes from studies 
of survivors of EBOV, SUDV, and BDBV infection. In this 
study, we provide the first comprehensive immune profiling 
of responses in human MARV survivors. Identification of a 
consensus immune response elicited by filovirus infection 
would be highly valuable for the evaluation of vaccines and 
therapeutics against MARV disease and those that would seek 
to be broadly protective.
rESultS And dIScuSSIon
t cell cytokine responses
Heparinized blood samples from six survivors of the 2012 
MARV outbreak in Uganda, as well as local individuals who 
had not been infected, were obtained ∼9 mo after the res-
olution of the outbreak. Our use of whole blood cultures 
to measure filovirus survivor immune responses has been 
described previously (Sobarzo et al., 2016). Whereas many 
valuable phenotypic analyses on bulk T cell populations 
have been conducted on acute-phase samples from EBOV- 
infected individuals (McElroy et al., 2015; Agrati et al., 2016; 
Ruibal et al., 2016), we deemed a functional analysis of vi-
rus-specific immune responses to be more informative, as the 
samples in our studies were far removed from the acute infec-
tion. Unfortunately, we were unable to procure acute-phase 
samples from the 2012 MARV outbreak; however, such phe-
notypic studies would be invaluable should samples be avail-
able in future outbreaks.
A representative set of flow cytometry plots for CD4+ 
and CD8+ T cell responses from a MARV survivor is shown 
in Fig. 1 A. Plots are gated sequentially on lymphocytes, sin-
glets, live cells, and CD3+, CD4+, or CD8+ events (Sobarzo et 
al., 2016). Resting, SUDV glycoprotein (GP), MARV GP, and 
irradiated SUDV cultures elicited minimal to no cytokine se-
cretion from either CD4+ or CD8+ T cells. Irradiated MARV 
stimulation elicited cytokine expression in survivor CD4+ T 
cells (Fig. 1 A, top), comprising IFN-γ and IL-2 double- and 
single-positive responses. Survivor CD8+ T cells (Fig. 1 A, 
bottom) displayed a more limited response, consisting almost 
exclusively of IFN-γ production. Cells from uninfected con-
trol individuals showed no reactivity to irradiated MARV or 
SUDV or the respective recombinant GP (not depicted).
Individual survivors’ CD4+ T cell responses are depicted 
in Fig. 1 B. IFN-γ and IL-2 single- or double-positive responses 
to irradiated MARV stimulation are shown for each survivor. 
Because only the irradiated MARV stimulation resulted in 
cytokine production, we focused further on that response to 
determine its composition. Resting values were subtracted to 
account for nonspecific responses. All but one survivor (S1) 
had IFN-γ single-positive responses, whereas all survivors 
had IFN-γ, IL-2 double-positive, and IL-2 single-positive re-
sponses. The magnitude of each individual’s response varied 
greatly, with some survivors having small but detectable re-
sponses (S1 and S6), whereas others were very robust (S2 and 
S5; Fig. 1 B). Levels of CD8+ T cell responses were low and 
did not permit a similar analysis (Fig. 1 A and not depicted).
Secreted cytokine analysis
To complement the flow cytometry analysis, we performed a 
multiplex ELI SA assay with the culture supernatants to ana-
lyze a broader range of secreted cytokines. We focused on five 
cytokines that are germane to adaptive immune responses: 
IL-2, IFN-γ, TNF, IL-4, and IL-5. Mean resting and irradiated 
SUDV-stimulated expression levels of each cytokine were 
low for uninfected control and survivor samples. MARV 
stimulation elicited IL-2, IFN-γ, and TNF expression that 
was significantly higher than resting and SUDV-stimulated 
cultures (P < 0.05; Fig. 2). IL-4 was not measured in any of 
the cultures, and only a slight, insignificant increase in IL-5 
expression was measured after irradiated MARV stimulation.
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cd40l expression and cytokine responses
Although we demonstrated the utility of whole blood cultures 
to measure T cell responses in MARV survivors (Fig. 1), the 
use of PBMCs allows for the analysis of greater cell numbers. 
Additionally, purified PBMCs can better elaborate cytokine 
responses in comparison to whole blood cultures (Hoff-
meister et al., 2003). We therefore developed an assay to use 
PBMCs instead of whole blood to attempt a more detailed 
and comprehensive analysis of T cell responses in MARV sur-
vivors. PBMCs were cultured with the specific antigens as be-
fore, except that monensin (instead of brefeldin A) was added 
after 2 h of culture to begin trapping intracellular cytokines. 
Additionally, fluorescently labeled antibodies against CD107a 
and CD40L were added at this time to enable detection of a 
degranulation phenotype (Betts et al., 2003) and CD4+ T cell 
activation (Chattopadhyay et al., 2006), respectively. Cultures 
were then incubated for a further 16 h. Cell viability gated 
on lymphocytes after culture (18 h total; 16 h with monen-
sin) was measured by an amine-reactive dye and found to 
be 91 ± 5.8% inclusive of all survivors and culture condi-
tions (unpublished data).
With a combination of CD40L and IFN-γ expression, 
we identified activated CD4+ T cells after stimulation with 
irradiated MARV antigen from seven MARV survivors from 
the 2012 outbreak. In our previous collection, we had only 
obtained samples from six survivors; however, in the interven-
ing time, we gained access to an additional survivor sample 
for flow cytometry analysis. IFN-γ expression was coordi-
nately expressed with CD40L, which is consistent with the 
description of CD40L expression as an activation marker 
Figure 1. Analysis of MArV survivor t cell responses in whole blood cultures. Heparinized whole blood samples were collected from MARV survivors 
(n = 6) ∼9 mo after the 2012 MARV outbreak in Uganda. (A) Representative IFN-γ and IL-2 responses in CD4+ and CD8+ T cells to recombinant SUDV GP or 
MARV GP, irradiated SUDV or MARV, and staphylococcus enterotoxin B for 22 h are shown. (B) The frequency of IFN-γ single-positive, IL-2 single-positive, 
or IFN-γ and IL-2 double-positive responses among total CD4+ T cells are shown for six MARV survivors.
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(Fig. 3 A, top; Chattopadhyay et al., 2006). TNF and IL-2 
expression also followed the same pattern with regard to 
CD40L expression (not depicted). PBMCs from uninfected 
controls demonstrated no cytokine response to the irradiated 
MARV antigen (Fig.  3  A, middle). Representative IFN-γ 
and TNF staining, gated on CD40L+ CD4+ T cells, is de-
picted in Fig. 3 A (bottom) for all survivors after irradiated 
MARV antigen stimulation.
To measure the overall magnitude of the CD4+ T cell 
response, we used a Boolean gating strategy to determine 
the frequency of IFN-γ−, TNF-, or IL-2–positive events 
that were identified by CD40L expression after stimulation 
(Fig.  3  B). CD40L expression has been shown to increase 
in a nonspecific manner during culture (Chattopadhyay et 
al., 2006), and this analysis enabled us to determine the fre-
quency of only cytokine-expressing CD40L+ CD4+ T cells to 
give a more accurate representation of the specific response. 
Resting, SUDV GP, and irradiated SUDV antigen cultures 
elicited negligible CD40L+ cytokine+ responses (Fig. 3 B), 
reinforcing both the utility and specificity of the stimulation 
and analysis. Furthermore, PBMC samples from uninfected 
controls exhibited no coordinate expression of CD40L and 
IFN-γ after stimulation with irradiated MARV, demonstrat-
ing that this response is specific to MARV survivors. MARV 
GP elicited responses of low magnitude, whereas the CD40L+ 
cytokine+ response to irradiated MARV was more robust in 
comparison (Fig. 3 B). CD4+ T cell responses directed against 
MARV GP were low in magnitude compared with irradi-
ated virus, as in Fig. 1, despite skewing the amount of anti-
gen toward favoring GP-specific responses. The composition 
of each individual survivor’s CD40L+ response to irradiated 
MARV stimulation in terms of IFN-γ, TNF, and IL-2 is de-
picted in Fig. 3 C. Resting culture values were subtracted to 
account for any background cytokine expression. The most 
dominant response was found to be cells producing IFN-γ, 
TNF, and IL-2, whereas the double- and single-positive 
responses for these cytokines varied to a greater extent 
among survivors (Fig. 3 C). 
We had measured CD8+ T cell responses in whole 
blood cultures previously (Fig. 1 and not depicted), but the 
IFN-γ and IL-2 cytokine responses were low in magnitude. 
We considered it possible that perhaps these parameters 
were not capturing the totality of the CD8+ T cell response. 
Therefore, we incorporated CD107a staining into our anal-
ysis to detect any CD8+ T cells that had degranulated and/
or produced cytokines in response to MARV antigens. To 
this end, we analyzed CD107a and IFN-γ expression after 
MARV stimulation. Control CD8+ T cells demonstrated no 
detectable IFN-γ expression in response to MARV stimula-
tion, whereas CD107a expression was found in both resting 
Figure 2. Multiplex ElI SA for secreted cytokines. Supernatant was collected after 22-h stimulation of whole blood cultures from MARV survivors (n = 
6) and uninfected controls (n = 5). Supernatants were analyzed in duplicate. Mean values for the indicated cytokine secretion are reported among survivor 
and control populations. * indicates P < 0.05 for irradiated MARV versus irradiated SUDV stimulations. # indicates P < 0.05 for irradiated MARV stimulation 
versus resting cultures. n.s. indicates no significant difference.
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and MARV-stimulated cultures. This apparently nonspecific 
CD107a expression was found in resting cultures for survi-
vors’ CD8+ T cells as well. CD107a expression in the context 
of IFN-γ and TNF (not depicted) demonstrated specificity 
with regard to MARV stimulation, and only in a subset of 
survivors (Fig. 4, right panels). These results confirm our ear-
lier findings showing little to no CD8+ T cell responses in 
MARV survivors and add the additional functional character-
istic of apparent cytotoxic responses.
CD4+ T cell responses to MARV were readily detect-
able in many cases, either in whole blood samples or purified 
PBMCs (Figs. 1 and 3). In contrast, CD8+ T cell responses were 
far more rare (Figs. 1 and 4), regardless of the sample type. Al-
though the CD8+ T cell response to EBOV is relatively well 
documented in survivors and nonsurvivors during infection 
or shortly after convalescence (McElroy et al., 2015; Agrati 
et al., 2016; Ruibal et al., 2016), still little is known about 
the long-term persistence of these responses. We demonstrate 
here that anti-MARV CD4+ T cell responses are present for 
at least 2 yr after infection. Furthermore, SUDV survivors’ 
CD4+ T cell responses have been shown to persist for more 
than a decade, whereas CD8+ T cell responses were far more 
rare (Sobarzo et al., 2016). Blood samples collected at the time 
of this SUDV outbreak demonstrated elevated CD8+ T cell 
counts in nonfatal cases (Sanchez et al., 2004), which suggests 
there was an active CD8+ T cell response that had diminished 
Figure 3. Flow cytometry analysis of MArV survivor cd4+ t cell responses in PBMc cultures. Purified PBMCs from MARV survivors (n = 7) and 
uninfected controls (n = 3) were collected 27 mo after the MARV outbreak and stimulated with antigens as before for a total of 18 h. Monensin, CD40L 
antibody, and CD107a antibody were added after 2 h. (A) CD40L and IFN-γ staining on CD4+ T cells after stimulation with irradiated MARV antigen. Top 
panels depict responses seen in survivors, and uninfected control responses are depicted in the middle panel. The bottom panel demonstrates IFN-γ and 
TNF staining after gating on CD40L+ CD4+ T cells from survivors as identified in the top panel. (B) Bar graph shows the frequency of total cytokine+ CD40L+ 
CD4+ T cells after stimulation with the indicated MARV and SUDV antigens. (C) Pie charts display the composition of the CD40L+ cytokine response in MARV 
survivors after stimulation with irradiated MARV.
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greatly over time. A similar phenomenon may have occurred 
with the MARV survivor immune responses we have re-
ported here, albeit over a shorter timescale. Indeed, a study of 
immune response in smallpox vaccine recipients showed that 
CD8+ T cell responses measured longitudinally diminished 
greatly over time and were present at very low frequencies 
when measured 2 yr after vaccination (Miller et al., 2008). 
Alternatively, CD4+ T cell cytokine responses were found 
to be of relatively lower magnitude compared with CD8+ T 
cell cytokine responses in EBOV survivors when assayed be-
tween 28 and 144 d after onset of symptoms (McElroy et al., 
2015). MARV and SUDV survivor immune responses, how-
ever, appear to heavily favor CD4+ T cell responses, though 
these studies were conducted with samples collected months 
and years after convalescence. Despite the difference in time 
frames, the MARV survivor CD4+ T cell cytokine responses 
we report in this study are of greater magnitude than those 
observed with EBOV survivors. These discordant immune re-
sponses among filovirus infection survivors may indicate that 
the composition of T cell responses to filovirus infection may 
vary significantly between MARV, EBOV, and SUDV.
Antiviral antibody responses
To address the humoral immune response to MARV infec-
tion, we collected serum from uninfected control donors 
and survivors and analyzed these samples for IgG antibodies 
against irradiated MARV antigen. Serum samples were seri-
ally diluted to determine an end titer. All survivors developed 
IgG responses to irradiated MARV, reaching an end titer be-
tween 4.25 and 6 (LOG10 serum dilutions; Fig. 5 A). Cell 
lysates expressing various MARV proteins were used to de-
termine the individual protein specificity of the MARV IgG 
response. Responses to lysate-derived antigens were denoted 
as + or − based on a signal-to-noise ratio of cell lysates with-
out MARV proteins (Table S1). All survivors were found to 
have IgG responses against MARV nucleoprotein (NP) and 
GP, but not against VP35 or VP24 (Table S1). Survivors 2–7 
had IgG responses to VP40, and survivors 1–6 had responses 
to VP30. Control sera were also included in these analyses 
and found to be nonreactive against lysates bearing MARV 
proteins (unpublished data). Antibody reactivity to MARV 
proteins is not likely to strictly be a consequence of relative 
protein abundance in the virion, as VP30 and VP24 constitute 
a similar fraction of overall virion protein content (Kiley et al., 
1988). However, MARV VP40 is roughly twice as abundant as 
VP35 in the MARV virion (Kiley et al., 1988), and both are 
described to be IFN antagonists (Valmas et al., 2010; Guito 
et al., 2017). Antibody reactivity in MARV survivor serum to 
VP40 and not VP35 may be reflective of either greater acces-
sibility to VP40 because of its greater abundance or its associ-
ation with the viral membrane. Though it is beyond the scope 
of our current studies, it would be intriguing to determine 
whether antibodies to VP40 can inhibit its IFN antagonism 
and/or its role in virion assembly, which could impute novel 
roles for antibody function in filovirus infections.
To address one potential function of the MARV-specific 
serum antibodies, we used a plaque reduction/neutralization 
test (PRNT) to determine whether survivor serum could 
neutralize live virus in vitro. Serum samples were serially di-
luted beginning at 1:10 and preincubated with MARV. This 
mixture was then used to inoculate Vero E6 cells, and result-
ing plaques were counted. Serum from only two survivors, S2 
and S3, neutralized MARV plaque formation by at least 50%, 
our predetermined threshold (Fig. 4 B). Uninfected control 
serum samples had very low neutralization values, illustrating 
the specificity of this response in MARV survivors. We evalu-
Figure 4. MArV survivor cd8+ t cell responses. PBMCs from MARV survivors (n = 4) and uninfected controls (n = 2) were cultured as before. Plots 
depict IFN-γ+ and CD107a+ CD8+ T cell responses after stimulation with irradiated MARV. Left panels depict staining of uninfected control samples. Right 
panels show representative staining of four MARV survivors with and without apparent CD8+ T cell responses. Positive CD8+ T cell responses are consid-
ered to be CD107a+ IFN-γ+.
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ated serological responses longitudinally with serum samples 
collected every 6 mo. For our purposes, we used a thresh-
old of ≥50% neutralization of MARV (PRNT50) to deter-
mine positive neutralization responses. For samples collected 
9 and 15 mo after the outbreak, two out of six survivors had 
neutralizing antibody titers between 1:20 and 1:40 (Fig. 3 B 
and Table S2). Neutralizing responses to MARV began to 
diminish 21 mo after the outbreak and dropped below our 
threshold after 27 mo. In contrast, antibody titers to irradiated 
MARV over this same time frame remained consistent with 
no drop in antibody end titer (Table S2).
Whereas our current knowledge of T cell responses to 
various filovirus infections suggests common themes, such as 
robust Th1-skewed CD4+ T cell responses, the antibody re-
sponses appear to be more divergent. MARV survivors gener-
ate IgG responses against GP, NP (all survivors), VP40 (S2 –7), 
and VP30 (S1–4, 6, and 7) but not to VP35 or VP24 (Table 
S1). These profiles of viral protein reactivity resemble the se-
rological profile of SUDV survivors (Sobarzo et al., 2013). 
Neutralizing antibody responses in MARV survivors, however, 
appear to be more divergent from that seen in SUDV survi-
vors. Analyses of survivors of the SUDV outbreak in Gulu, 
Uganda, demonstrate long-lived neutralizing antibody titers 
(Sobarzo et al., 2013). Admittedly, this particular MARV co-
hort is small in number (n = 8); however, in a similar sample 
size from a recent SUDV outbreak in Kibaale, Uganda (Al-
bariño et al., 2013), five out of five survivors had neutralizing 
serum responses (Sobarzo et al., 2015). Even more striking 
is the magnitude of neutralizing titers among recent SUDV 
survivors: three out of five had PRNT50 values ≥1/80. Neu-
tralizing antibody responses in a MARV survivor have been 
previously reported (Flyak et al., 2015), but our data are the 
first longitudinal analyses to demonstrate a decline in these re-
sponses, despite maintaining high antibody titers overall. Our 
first serum samples were obtained ∼9 mo after the outbreak, 
so it remains possible that all survivors may have had neutraliz-
ing responses at time points more proximal to infection. What 
is clear, however, is that these responses are lower in magnitude 
than analogous SUDV survivors (Sobarzo et al., 2015).
Neutralizing antibody responses have been achieved 
through vaccination against MARV GP in mouse, guinea pig, 
and cynomolgus macaques (Shedlock et al., 2013; Grant-Klein 
et al., 2015). Interestingly, cynomolgus macaques vaccinated 
against MARV GP showed diminishing neutralizing antibody 
titers over time (Mire et al., 2014), similar to our observa-
tions with human survivors of MARV infection. It would 
be interesting to see whether a similar phenomenon would 
occur in any surviving naive macaques that were experimen-
tally infected with MARV. Whereas neutralizing antibodies 
elicited by vaccination against filoviruses is a coveted immune 
response, functions of nonneutralizing antibodies have been 
described in other viral immune responses. Nonneutralizing 
antibodies to HIV and lymphocytic choriomeningitis virus 
GPs inhibit infection of DCs and macrophages (Holl et al., 
2006) and limit virus spread (Hangartner et al., 2006), respec-
tively. Various nonneutralizing functions of antibodies elicited 
by vaccination against HIV have been described previously 
in great detail (Chung et al., 2014, 2015). Perhaps more in-
triguing is a study showing that nonneutralizing antibodies 
elicited by vaccination against influenza NP can play a role in 
aiding the T cell response in protecting mice against influenza 
infection (Carragher et al., 2008). Indeed, immunization with 
influenza–NP antibody complexes elicited IFN-γ production 
from CD8+ and CD4+ T cells (Zheng et al., 2007), indicating 
a Th1-skewed immune response. Because all the MARV sur-
vivors in this have antibodies recognizing MARV NP (Table 
S1), these studies describing a role for NP-specific antibodies 
in T cell responses may provide a roadmap for the ontogeny 
of the MARV survivor immune responses described herein.
Our studies are the first to provide a detailed longitu-
dinal analysis of immune responses among human MARV 
Figure 5. Antibody responses from MArV survivors. (A) Irradiated 
MARV was coated on plates to capture MARV-specific antibodies from 
serum samples collected from MARV survivors (n = 5) and uninfected con-
trols (n = 3). Total IgG was detected using an anti–human IgG-HRP antibody 
and ABTS substrate. End titer is reported as the antilog of the reciprocal of 
the last dilution of serum that exceeds a threshold based on naive serum. 
The limit of detection is depicted by the dashed line. (B) Beginning at 1:10, 
serial 1:2 dilutions of serum samples from MARV survivors (n = 6) and 
uninfected controls (n = 5) were incubated with MARV before inoculation 
of Vero E6 cells. The percentage of neutralization is reported at 1:10, 1:20, 
1:40, and 1:80 dilutions based on the reduction of plaques relative to con-
trol MARV-infected Vero cells. Dashed line indicates 50% neutralization, 
or PRNT50, which is used to define positive neutralizing responses. Serum 
samples used in ELI SA and PRNT were analyzed in duplicate.
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survivors. Our findings highlight that although CD4+ T cell 
responses may be common among human filovirus survivors, 
the neutralizing antibody response varies to a greater degree. 
The discord in neutralizing responses between MARV and 
SUDV survivors indicates that there is a critical knowledge 
gap regarding what can be considered a protective response 
to filovirus infection.
MAtErIAlS And MEthodS
Study design
Subjects included confirmed survivors, according to patient 
PCR and ELI SA results, from the MARV outbreak of 2012 in 
the Ibanda and Kabale districts of Uganda, as well as healthy 
local community members that were not infected. Based on 
records obtained from the Centers for Disease Control in 
Uganda, we identified a total of 10 survivors from this out-
break. We were able to collect from eight of these survivors, 
with the others not being available or too young in age for 
collections. Whole blood stimulations were conducted with 
blood samples from six survivors, and PBMC stimulations 
were conducted with samples from seven survivors. Survivors 
in these studies ranged in age from 18 to 50 yr. Whole blood 
analyses involved two male and four female survivors, and 
PBMC analyses included three male and four female survi-
vors. An additional survivor (S7, female) for whom we have 
serological data but not flow cytometry data is included in 
Tables S1 and S2. Health questionnaires administered before 
sample collection indicated that the study subjects were rel-
atively healthy, with a few individuals reporting nonspecific 
malaise. One survivor was receiving medication for malaria.
Ethics statement
The study was approved by the Helsinki committees of 
the Uganda Virus Research Institute in Entebbe, Uganda 
(reference number GC/127/13/01/15); Soroka Hospi-
tal, Beer-sheva, Israel (protocol number 0263–13-SOR); 
and the Ugandan National Council for Science and Tech-
nology (registration number HS1332). Written informed 
consent as well as a personal health questionnaire was com-
pleted for each subject.
Flow cytometry assays
Whole blood cultures were established as previously reported 
(Sobarzo et al., 2016). In brief, 0.25 ml of fresh whole blood 
was mixed with 0.75 ml RPMI medium and 5% FBS, and 
cultures were incubated with 50 µg MARV or SUDV GPs or 
10 µg of noninfectious irradiated whole virus preparations of 
MARV (MARV/Homo sapiens–tc/DEU/1967/Hesse-Ci67) 
or SUDV (SUDV/Homo sapiens–tc/UGA/2000/Gulu). The 
amount of antigen used for stimulation was titrated using sur-
vivor samples from an unrelated SUDV outbreak in 2000-
2001. In these studies, cultures were supplemented after 
18 h with brefeldin A and incubated for a further 4 h. After 
22  h total, cultures were vortexed, cells were pelleted, and 
the resultant supernatant was collected. Cells were subjected 
to two 5-min incubations with a Tris–ammonium chloride 
solution to lyse red blood cells and then subsequently stained 
for surface and intracellular antigens. This approach enabled 
a flow cytometry analysis of cytokine response with matched 
supernatants for an expanded cytokine analysis by ELI SA. 
PBMCs were collected in cell preparation tube vacutainers 
(BD Biosciences) and isolated according to the manufactur-
er’s protocol. Total cell yields were split between various cul-
ture conditions in RPMI medium + 5% FBS: no stimulation, 
50 µg recombinant MARV or SUDV GP, 10 µg of irradiated 
MARV or SUDV, or 1 µg staphylococcus enterotoxin B. Cul-
ture volume across all conditions was 1 ml. After 2 h, cultures 
were supplemented with monensin and antibodies against 
CD40L and CD107a. Total culture time was 18 h. After stim-
ulation, cells were stained with the amine-reactive Aqua dye 
(Thermo Fisher) to detect dead cells, nonspecific staining was 
blocked with 1% mouse serum, and surface proteins were 
stained with fluorescently labeled antibodies. After fixation 
and permeabilization, intracellular cytokines were detected. 
Samples were acquired on an LSR II flow cytometer (BD 
Biosciences) at the Uganda Virus Research Institute/Medical 
Research Council facilities in Entebbe, Uganda. Flowjo (ver-
sion X; Treestar) was used to analyze flow cytometry data. An-
tibodies used in these studies are as follows: CD3 (S4.1/Qdot 
605 for whole blood and UCHT1/BV650 for PBMCs), 
CD4 (S3.5/Qdot 655 for whole blood and RPA-T4/BV605 
for PBMCs), CD8 (3B5/Qdot 705 for whole blood and 
SK1/BV711 for PBMCs), CD40L (TRAP1/PE), CD107a 
(eBioH4A3/eFluor660), IFN-γ (4S.B3/APC-eFluor780), 
IL-2 (MQ1-17H12/PE-Cy7), and TNF (MAb11/FITC).
Prnt
PRNTs were performed as previously described (Sobarzo et 
al., 2016). Neutralization titers were determined to be the last 
dilution of serum that reduced the number of plaques by 50% 
compared with control wells. Plaque reduction neutralization 
assays were performed in the BSL-4 laboratory of the United 
States Army Medical Research Institute of Infectious Diseases.
cytokine and chemokine detection using Q-Plex ElI SA- 
based chemiluminescent assay
Levels of human cytokines were measured in whole blood 
culture supernatants using Q-Plex technology (Quansys 
Biosciences) according to the manufacturer’s instructions. 
Readouts were obtained with a Quansys Imager (Quansys 
Biosciences), and results were analyzed using the Q-View 
Software program (Quansys Biosciences).
ElI SA antigens
For ELI SA assays, irradiated MARV (Ci67 isolate), recom-
binant MARV GP1–649, and total 293T cell lysate that ex-
pressed a given recombinant MARV protein (NP, VP24, 
and VP35) were used as the capture antigens. Total IgG was 
detected with an anti–human IgG antibody conjugated to 
HRP. 2,2′-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) 
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(KPL) was used as the substrate for irradiated MARV end 
titer ELI SAs, and a chemiluminescent substrate was used in 
ELI SAs for viral proteins.
Statistical analysis
Statistical analyses were performed using Prism software (ver-
sion 6.01; GraphPad). Correlation analysis was assessed by the 
Spearman nonparametric test. Differences in cytokine values 
between study groups were assessed by ANO VA and Wil-
coxon rank sum test; p-values represent two-sided p-values, 
and p-values <0.05 were considered statistically significant.
online supplemental material
Table S1 shows MARV survivor serum reactivity to individ-
ual MARV proteins. Table S2 shows a longitudinal analysis of 
anti-MARV serum antibody responses by ELI SA and PRNT.
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Table S1. MARV survivor serum reactivity to individual virus proteins
Survivor GP NP VP35 VP24 VP40 VP30 Whole virus
S1 + + − − − + +
S2 + + − − + + +
S3 + + − − + + +
S4 + + − − + + +
S5 + + − − − − +
S6 + + − − + + +
S7 + + − − + + +
S8 + + − − + − +
MARV proteins were expressed in 293T cells, and cell lysates were used as ELI SA capture antigens. Antibody responses were scored as positive or negative based on the signal-to-noise ratio 
of MARV protein-transfected lysates and nontransfected lysates.
Table S2. Longitudinal analysis of antibody responses
Survivor Time of collection after outbreak
9 mo 15 mo 21 mo 27 mo 33 mo
S1 PRNT50 <10 <10 <10 <10 <10
End titer 4.25 4 4 3.75 4
S2 PRNT50 20 20 10 <10 <10
End titer 6 5.75 5.5 5.5 6
S3 PRNT50 40 40 n.d. <10 <10
End titer 5.5 5.0 5.5 6 5.5
S4 PRNT50 <10 10 <10 <10 <10
End titer 4.5 4.5 4.25 4.0 4.5
S5 PRNT50 <10 <10 <10 <10 <10
End titer 4.5 4 4.5 4.5 4.5
S6 PRNT50 <10 <10 <10 <10 <10
End titer 4.5 4.5 4.75 5.5 6
S7 PRNT50 n.d. 10 n.d. n.d. n.d.
End titer n.d. 4.5 n.d. n.d. n.d.
S8 PRNT50 n.d. <10 <10 <10 <10
End titer n.d. 4.5 n.d. 4.75 4.75
Antibody end titer and PRNT50 titers are shown at 6-mo intervals beginning 9 mo after the end of the 2012 MARV outbreak in Uganda. n.d. indicates that a value was not determined because 
of sample unavailability. All serum samples were analyzed in duplicate.
